Efficacy and relapse profiles of Pola‐R‐ <scp>CHP</scp> versus R‐ <scp>CHOP</scp> in previously untreated diffuse large B‐cell lymphoma: A multicentre real‐world study
Toshiki Terao(Okayama University), Yoshinobu Maeda(The University of Osaka), Hideaki Fujiwara(Okayama University Hospital), Daisuke Ennishi(BC Cancer Agency), Daigo Niiya(Okayama Psychiatric Medical Center), Tomohiro Urata(Okayama University Hospital), Isao Yoshida(Okayama Psychiatric Medical Center), Shoji Asakura(Eisai (Japan)), Kyosuke Saeki(Ehime Prefectural Central Hospital), Fuminari Fujii(Kameda Medical Center), Hisakazu Nishimori(Hiroshima City Asa Citizens Hospital), Hiroki Kobayashi(Okayama Psychiatric Medical Center), Hiroyuki Sugiura(Fukuyama City Hospital), Yusuke Meguri(Okayama University Hospital), Daisuke Ikeda(Okayama University Hospital), Takanori Yoshioka(Okayama Psychiatric Medical Center)
Cited by 0
Related Papers
Gut microbiome–derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease
|Nature Immunology|2016|727
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry
|The Lancet Oncology|2015|613
Microbial metabolite sensor GPR43 controls severity of experimental GVHD
|Nature Communications|2018|161
Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma
|Nature Communications|2018|148